Clinical Trials Browser

Active not recruiting × enfortumab vedotin × 30 days × Clear all

NCT04960709 2026-06-04

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04223856 2026-05-29

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms